ORBi: Langlet P. - A randomized trial of pegylated-interferon alpha 2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients

Reference : A randomized trial of pegylated-interferon alpha 2a plus ribavirin with or without amant...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Gastroenterology & hepatology
	To cite this reference:	http://hdl.handle.net/2268/66821

Title :	A randomized trial of pegylated-interferon alpha 2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients
Language :	English
Author, co-author :	Langlet, P. [CHU Brugmann > > > >]
	D'Heygere, F. [CAZK Groeninghe > > > >]
	Henrion, J. [Hopital de Jolimont > > > >]
	Adler, M. [Hopital Universitaire Erasme > > > >]
	Delwaide, Jean [Université de Liège - ULg > > Gastro-Entérologie-Hépatologie >]
	Van Vlierberghe, H. [UZ Gent > > > >]
	Mulkay, J. P. [CHU Saint-Pierre > > > >]
	Lasser, L. [CHU Brugmann > > > >]
	Brenard, R. [Clinique St-Joseph, Gilly > > > >]
	Horsmans, Y. [Clinique Universitaire St Luc > > > >]
	Michielsen, P. [UZ Antwerpen > > > >]
	Laureys, A. [Roche NV ⁄ SA, Brussels > > > >]
	Nevens, F. [UZ Gasthuisberg, Leuven > > > >]
Publication date :	2009
Journal title :	Alimentary Pharmacology & Therapeutics
Publisher :	Blackwell Publishing
Volume :	30
Pages :	352-363
Audience :	International
ISSN :	0269-2813
e-ISSN :	1365-2036
City :	Oxford
Country :	United Kingdom
Keywords :	[en] amantadine ; ribavirin ; pegylated-interferon-a2a ; chronic hepatitis C ; treatment
Abstract :	[en] Background The combination therapy of pegylated-interferon-a2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. A sustained viral response is obtained in 40–50% of naı¨ve patients with genotype 1 and in around 80% of naı¨ve patients with genotype 2 or 3. Aim To assess whether amantadine, added to the conventional combination therapy, could improve the treatment efficacy. Methods In all, 630 patients (intent-to-treat population) with chronic hepatitis C were randomized into two groups: 316 patients (treatment group) received pegylated-interferon-a2a (180 lg once weekly) plus ribavirin (1000–1200 mg⁄ daily) with amantadine (200 mg⁄ daily); 314 patients (control group) received pegylated-interferon-a2a (180 lg once weekly) plus ribavirin (1000–1200 mg⁄ daily) without amantadine. The duration of the treatment was 48 weeks for genotypes 1, 4, 5 and 6, and 24 weeks for genotypes 2 and 3. Results There was no statistically significant difference between treatments groups for any of the variables tested for. Subgroups of patients likely to take advantage of the addition of amantadine were not identified. Conclusions This large study definitely excludes the role of amantadine in addition of conventional combination therapy in the treatment of chronic hepatitis C patients.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/66821
DOI :	10.1111/j.1365-2036.2009.04052.x

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	Delwaide_2009_AlimentPharmacol_352.pdf		Publisher postprint	134.16 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5